Identification

Name
Acemetacin
Accession Number
DB13783
Type
Small Molecule
Groups
Approved, Experimental, Investigational
Description

Acemetacin is a carboxymethyl ester of indometacin. It is a potent non-steroidal anti-inflammatory drug, derived from the indol-3-acetic acid, whose activity is thought to be mainly through its active metabolite indomethacin.[1] In clinical trials, acemetacin exhibits a better gastric tolerability compared to its active metabolite indometacin.[6] It was developed by E. Merck and Company in Germany as an attempt to provide a safer drug but other than the amelioration on the gastrointestinal effects, the metabolism of acetamicin led to the formation of indomethacin and it kept the same side effects.[7]

Structure
Thumb
Synonyms
  • acemetacina
  • acemetacine
  • acemetacinum
  • indometacin carboxymethyl ester
  • indometacin glycolic ester
  • indomethacin carboxymethyl ester
  • indomethacin glycolic ester
External IDs
K 708 / K-708 / TV-1322 / TVX 3322
International/Other Brands
Acemetacin Heumann (Heumann) / Acemetacin Stada (Stada) / Acemetacin von ct (ct-Arzneimittel) / Acemix (Bioprogress) / Altren (Rorer) / Analgen (Celtia) / Emflex (Merck Serono) / Esplendol (Fher) / Flamarion (Syncro) / Gynalgia (Syncro) / Mostanol (Boehringer Ingelheim) / Oldan (Europharma) / Rantudil (Bayer or Bial) / Rheutrop (Kolassa or Tropon) / Solart (Bioindustria) / Tilur (Drossapharm)
Categories
UNII
5V141XK28X
CAS number
53164-05-9
Weight
Average: 415.83
Monoisotopic: 415.082265
Chemical Formula
C21H18ClNO6
InChI Key
FSQKKOOTNAMONP-UHFFFAOYSA-N
InChI
InChI=1S/C21H18ClNO6/c1-12-16(10-20(26)29-11-19(24)25)17-9-15(28-2)7-8-18(17)23(12)21(27)13-3-5-14(22)6-4-13/h3-9H,10-11H2,1-2H3,(H,24,25)
IUPAC Name
2-({2-[1-(4-chlorobenzoyl)-5-methoxy-2-methyl-1H-indol-3-yl]acetyl}oxy)acetic acid
SMILES
COC1=CC2=C(C=C1)N(C(=O)C1=CC=C(Cl)C=C1)C(C)=C2CC(=O)OCC(O)=O

Pharmacology

Indication

Acemetacin is not FDA, Canada or EMA approved, but in the countries where it is marketed it is indicated for the symptomatic treatment of pain and swelling in acute inflammation of the joints in rheumathoid arthritis, osteoarthritis, low back pain and post-surgical pain.[11] It is also indicated for the treatment of chronic inflammation of the joints in presence of rheumatoid arthritis, treatment of ankylosing spondylitis, treatment of irritation in the joints and spinal column caused by degenerative disorders, treatment of inflammatory soft-tissue rheumatism syndrome and painful swelling and inflammation caused by injury.[10, 12]

Structured Indications
Not Available
Pharmacodynamics

The effect of acemetacin causes a weak reduction of prostaglandin synthesis which generates an anti-inflammatory and analgesic effect. The weak inhibition of prostaglandin reduces significantly the damage caused in the mucous membrane of the gastrointestinal tract. Studies have shown that acemetacin strongly inhibits the release of histamine from mast cells and the generation of hyperthermia. Acemetacin effect also causes changes in systolic and diastolic blood pressure as well as inhibition of platelet aggregation.[2]

Mechanism of action

Acemetacin is a non-selective inhibitor of the production of pro-inflammatory mediators derived from the action of the enzyme COX. COX is essential for the synthesis of prostaglandin E2 and F2 which are molecules derived from fatty acids and stored in the cell membrane.[8] Acetometacine is metabolized and forms its major metabolite indometacin which is also a non-selective inhibitor of COX and exhibits the capacity to inhibit the motility of polymorphonuclear leukocytes and decreased cerebral flow by modulating the nitric oxide pathway and vasoconstriction.[7]

TargetActionsOrganism
AProstaglandin G/H synthase 1
antagonist
Human
AProstaglandin G/H synthase 2
antagonist
Human
Absorption

After 8 days of oral administration twice daily of acemetacin there was an age-dependant Cmax of 276.8 ng/ml in elderly compared to 187 ng/ml for younger individuals. There was also a Tmax of 2.5 h and AUC in a range of 483-712 ng h/ml.[3] The bioavailability of acemetacin after repeated doses is aproximately 66% in plasma and 64% in urine.[4]

Volume of distribution

The apparent volume of distribution of acemetacin is in a range of 0.5-0.7 L/kg.[9]

Protein binding

Acemetacin is found highly bound to plasma proteins, reaching a percentage higher than 90% of the administered dose.[9]

Metabolism

Acemetacin is highly metabolized and degraded by esterolytic cleavage to form its major and active metabolite indometacin. It presents other inactive metabolites made by reaction of O-demethylation, N-desacylation and part of them are also transformed by conjugation with glucuronic acid.[9]

Route of elimination

The elimination of acemetacin is divided in renal elimination that covers 40% of the complete administered dose and the restant 60% is excreted in feces.[9]

Half life

The elimination half-life of acemetacin after steady-state is 4.5 hours.[4]

Clearance

Intravenous administration of acemetacin in healthy subjects reported a clearance rate of 4.59 ml min/kg.[5]

Toxicity

The pharmacological activity of acemetacin causes blockage of prostaglandin synthesis. Prostaglandin is one of the mediators of renal blood flow and glomerular filtration thus, acemetacin causes a decreased renal function, transient renal insufficiency, interstitial nephritis and papillary necrosis especially in elderly patients, patients with congestive heart failure, hepatic cirrhosis and impaired renal function.[9]

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
(4R)-limoneneThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Acemetacin.Investigational
16-BromoepiandrosteroneThe risk or severity of adverse effects can be increased when Acemetacin is combined with 16-Bromoepiandrosterone.Investigational
19-norandrostenedioneThe risk or severity of adverse effects can be increased when Acemetacin is combined with 19-norandrostenedione.Experimental, Illicit
5-androstenedioneThe risk or severity of adverse effects can be increased when Acemetacin is combined with 5-androstenedione.Experimental, Illicit
AbciximabThe risk or severity of bleeding can be increased when Abciximab is combined with Acemetacin.Approved
AcebutololThe therapeutic efficacy of Acebutolol can be decreased when used in combination with Acemetacin.Approved, Investigational
AceclofenacThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Acemetacin.Approved, Investigational
AcenocoumarolThe risk or severity of bleeding can be increased when Acenocoumarol is combined with Acemetacin.Approved, Investigational
AcetazolamideThe therapeutic efficacy of Acetazolamide can be decreased when used in combination with Acemetacin.Approved, Vet Approved
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Acemetacin.Approved, Vet Approved
AclarubicinAcemetacin may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Investigational
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Acemetacin.Approved
AdrenaloneThe therapeutic efficacy of Acemetacin can be decreased when used in combination with Adrenalone.Experimental
AlclofenacThe risk or severity of adverse effects can be increased when Alclofenac is combined with Acemetacin.Approved, Withdrawn
AlclometasoneThe risk or severity of adverse effects can be increased when Acemetacin is combined with Alclometasone.Approved
AldosteroneThe risk or severity of adverse effects can be increased when Acemetacin is combined with Aldosterone.Experimental, Investigational
AldoxorubicinAcemetacin may decrease the excretion rate of Aldoxorubicin which could result in a higher serum level.Investigational
Alendronic acidThe risk or severity of adverse effects can be increased when Acemetacin is combined with Alendronic acid.Approved
AliskirenThe therapeutic efficacy of Aliskiren can be decreased when used in combination with Acemetacin.Approved, Investigational
AlminoprofenThe risk or severity of adverse effects can be increased when Alminoprofen is combined with Acemetacin.Experimental
AlprenololThe therapeutic efficacy of Alprenolol can be decreased when used in combination with Acemetacin.Approved, Withdrawn
AlprostadilThe therapeutic efficacy of Alprostadil can be decreased when used in combination with Acemetacin.Approved, Investigational
AmbrisentanThe therapeutic efficacy of Ambrisentan can be decreased when used in combination with Acemetacin.Approved, Investigational
AmcinonideThe risk or severity of adverse effects can be increased when Acemetacin is combined with Amcinonide.Approved
AmikacinAcemetacin may decrease the excretion rate of Amikacin which could result in a higher serum level.Approved, Investigational, Vet Approved
AmilorideThe therapeutic efficacy of Amiloride can be decreased when used in combination with Acemetacin.Approved
AmlodipineThe therapeutic efficacy of Amlodipine can be decreased when used in combination with Acemetacin.Approved
AmoxicillinAcemetacin may decrease the excretion rate of Amoxicillin which could result in a higher serum level.Approved, Vet Approved
AmpicillinAcemetacin may decrease the excretion rate of Ampicillin which could result in a higher serum level.Approved, Vet Approved
AmrubicinAcemetacin may decrease the excretion rate of Amrubicin which could result in a higher serum level.Approved, Investigational
AncrodThe risk or severity of bleeding can be increased when Ancrod is combined with Acemetacin.Approved, Investigational
AndrographolideThe risk or severity of adverse effects can be increased when Andrographolide is combined with Acemetacin.Investigational
AndrostenedioneThe risk or severity of adverse effects can be increased when Acemetacin is combined with Androstenedione.Experimental, Illicit
AnecortaveThe risk or severity of adverse effects can be increased when Acemetacin is combined with Anecortave.Investigational
anecortave acetateThe risk or severity of adverse effects can be increased when Acemetacin is combined with anecortave acetate.Investigational
AnisodamineThe risk or severity of adverse effects can be increased when Anisodamine is combined with Acemetacin.Investigational
AnnamycinAcemetacin may decrease the excretion rate of Annamycin which could result in a higher serum level.Investigational
AntipyrineThe risk or severity of adverse effects can be increased when Antipyrine is combined with Acemetacin.Approved, Investigational
Antithrombin III humanThe risk or severity of bleeding can be increased when Antithrombin III human is combined with Acemetacin.Approved
ApixabanThe risk or severity of bleeding can be increased when Apixaban is combined with Acemetacin.Approved
ApocyninThe risk or severity of adverse effects can be increased when Apocynin is combined with Acemetacin.Investigational
ApramycinAcemetacin may decrease the excretion rate of Apramycin which could result in a higher serum level.Experimental, Vet Approved
ApremilastThe risk or severity of adverse effects can be increased when Apremilast is combined with Acemetacin.Approved, Investigational
ArbekacinAcemetacin may decrease the excretion rate of Arbekacin which could result in a higher serum level.Approved, Investigational
ArdeparinThe risk or severity of bleeding can be increased when Ardeparin is combined with Acemetacin.Approved, Investigational, Withdrawn
ArformoterolThe therapeutic efficacy of Acemetacin can be decreased when used in combination with Arformoterol.Approved, Investigational
ArgatrobanThe risk or severity of bleeding can be increased when Argatroban is combined with Acemetacin.Approved, Investigational
ArotinololAcemetacin may decrease the antihypertensive activities of Arotinolol.Investigational
AtamestaneThe risk or severity of adverse effects can be increased when Acemetacin is combined with Atamestane.Investigational
AtenololThe therapeutic efficacy of Atenolol can be decreased when used in combination with Acemetacin.Approved
AZ-002The therapeutic efficacy of Acemetacin can be decreased when used in combination with AZ-002.Investigational
AzapropazoneThe risk or severity of adverse effects can be increased when Azapropazone is combined with Acemetacin.Withdrawn
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Acemetacin.Approved
Azficel-TThe risk or severity of adverse effects can be increased when Acemetacin is combined with Azficel-T.Approved, Investigational
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Acemetacin.Approved, Investigational
AzosemideThe therapeutic efficacy of Azosemide can be decreased when used in combination with Acemetacin.Investigational
BalsalazideThe risk or severity of adverse effects can be increased when Balsalazide is combined with Acemetacin.Approved, Investigational
BambuterolThe therapeutic efficacy of Acemetacin can be decreased when used in combination with Bambuterol.Approved, Investigational
BamethanThe therapeutic efficacy of Acemetacin can be decreased when used in combination with Bamethan.Experimental
BecaplerminThe risk or severity of bleeding can be increased when Becaplermin is combined with Acemetacin.Approved, Investigational
Beclomethasone dipropionateThe risk or severity of adverse effects can be increased when Acemetacin is combined with Beclomethasone dipropionate.Approved, Investigational
BefunololAcemetacin may decrease the antihypertensive activities of Befunolol.Experimental
BekanamycinAcemetacin may decrease the excretion rate of Bekanamycin which could result in a higher serum level.Experimental
BenazeprilThe therapeutic efficacy of Benazepril can be decreased when used in combination with Acemetacin.Approved, Investigational
BendazacThe risk or severity of adverse effects can be increased when Bendazac is combined with Acemetacin.Experimental
BendroflumethiazideThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Acemetacin.Approved
BenorilateThe risk or severity of adverse effects can be increased when Benorilate is combined with Acemetacin.Experimental
BenoxaprofenThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Acemetacin.Withdrawn
Benzathine benzylpenicillinAcemetacin may decrease the excretion rate of Benzathine benzylpenicillin which could result in a higher serum level.Approved, Vet Approved
BenzydamineThe risk or severity of adverse effects can be increased when Benzydamine is combined with Acemetacin.Approved
BenzylpenicillinAcemetacin may decrease the excretion rate of Benzylpenicillin which could result in a higher serum level.Approved, Vet Approved
BepridilThe therapeutic efficacy of Bepridil can be decreased when used in combination with Acemetacin.Approved, Withdrawn
BeraprostThe therapeutic efficacy of Beraprost can be decreased when used in combination with Acemetacin.Investigational
BetamethasoneThe risk or severity of adverse effects can be increased when Acemetacin is combined with Betamethasone.Approved, Vet Approved
BetaxololThe therapeutic efficacy of Betaxolol can be decreased when used in combination with Acemetacin.Approved, Investigational
BethanidineThe therapeutic efficacy of Bethanidine can be decreased when used in combination with Acemetacin.Approved
BetrixabanThe risk or severity of bleeding can be increased when Betrixaban is combined with Acemetacin.Approved, Investigational
BevantololAcemetacin may decrease the antihypertensive activities of Bevantolol.Approved
BevoniumThe risk or severity of adverse effects can be increased when Bevonium is combined with Acemetacin.Experimental
BietaserpineThe therapeutic efficacy of Bietaserpine can be decreased when used in combination with Acemetacin.Experimental
BimatoprostThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Acemetacin.Approved, Investigational
BisoprololThe therapeutic efficacy of Bisoprolol can be decreased when used in combination with Acemetacin.Approved
BitolterolThe therapeutic efficacy of Acemetacin can be decreased when used in combination with Bitolterol.Withdrawn
BivalirudinThe risk or severity of bleeding can be increased when Bivalirudin is combined with Acemetacin.Approved, Investigational
BopindololAcemetacin may decrease the antihypertensive activities of Bopindolol.Approved
BosentanThe therapeutic efficacy of Bosentan can be decreased when used in combination with Acemetacin.Approved, Investigational
BQ-123The therapeutic efficacy of BQ-123 can be decreased when used in combination with Acemetacin.Investigational
BretyliumThe therapeutic efficacy of Bretylium can be decreased when used in combination with Acemetacin.Approved
BrimonidineThe therapeutic efficacy of Brimonidine can be decreased when used in combination with Acemetacin.Approved
BromfenacThe risk or severity of adverse effects can be increased when Bromfenac is combined with Acemetacin.Approved
BucillamineThe risk or severity of adverse effects can be increased when Bucillamine is combined with Acemetacin.Investigational
BucindololAcemetacin may decrease the antihypertensive activities of Bucindolol.Investigational
BudesonideThe risk or severity of adverse effects can be increased when Acemetacin is combined with Budesonide.Approved
BufexamacThe risk or severity of adverse effects can be increased when Bufexamac is combined with Acemetacin.Approved, Experimental
BufuralolThe therapeutic efficacy of Acemetacin can be decreased when used in combination with Bufuralol.Experimental, Investigational
BumadizoneThe risk or severity of adverse effects can be increased when Bumadizone is combined with Acemetacin.Experimental
BumetanideThe therapeutic efficacy of Bumetanide can be decreased when used in combination with Acemetacin.Approved
BupranololThe therapeutic efficacy of Bupranolol can be decreased when used in combination with Acemetacin.Approved
ButyrylthiocholineThe therapeutic efficacy of Acemetacin can be decreased when used in combination with Butyrylthiocholine.Experimental
CadralazineThe therapeutic efficacy of Cadralazine can be decreased when used in combination with Acemetacin.Experimental
CafedrineThe therapeutic efficacy of Cafedrine can be decreased when used in combination with Acemetacin.Investigational
CandesartanThe therapeutic efficacy of Candesartan can be decreased when used in combination with Acemetacin.Experimental
Candesartan cilexetilThe therapeutic efficacy of Candesartan cilexetil can be decreased when used in combination with Acemetacin.Approved
CandoxatrilThe therapeutic efficacy of Candoxatril can be decreased when used in combination with Acemetacin.Experimental
Canrenoic acidThe therapeutic efficacy of Canrenoic acid can be decreased when used in combination with Acemetacin.Approved, Withdrawn
CanrenoneThe therapeutic efficacy of Canrenone can be decreased when used in combination with Acemetacin.Investigational
CaptoprilThe therapeutic efficacy of Captopril can be decreased when used in combination with Acemetacin.Approved
CarbacholThe therapeutic efficacy of Acemetacin can be decreased when used in combination with Carbachol.Approved
Carbaspirin calciumThe risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Acemetacin.Experimental, Investigational
Carboprost TromethamineThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Acemetacin.Approved
CarbuterolThe therapeutic efficacy of Acemetacin can be decreased when used in combination with Carbuterol.Experimental
CarprofenThe risk or severity of adverse effects can be increased when Carprofen is combined with Acemetacin.Approved, Vet Approved, Withdrawn
CarteololThe therapeutic efficacy of Carteolol can be decreased when used in combination with Acemetacin.Approved
CarvedilolThe therapeutic efficacy of Carvedilol can be decreased when used in combination with Acemetacin.Approved, Investigational
CastanospermineThe risk or severity of adverse effects can be increased when Castanospermine is combined with Acemetacin.Experimental
CelecoxibThe risk or severity of adverse effects can be increased when Celecoxib is combined with Acemetacin.Approved, Investigational
CeliprololThe therapeutic efficacy of Celiprolol can be decreased when used in combination with Acemetacin.Approved, Investigational
CertoparinThe risk or severity of bleeding can be increased when Certoparin is combined with Acemetacin.Approved, Investigational
ChloroquineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Acemetacin.Approved, Investigational, Vet Approved
ChlorothiazideThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Acemetacin.Approved, Vet Approved
ChlorthalidoneThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Acemetacin.Approved
CholestyramineCholestyramine can cause a decrease in the absorption of Acemetacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
CholineThe therapeutic efficacy of Acemetacin can be decreased when used in combination with Choline.Approved, Nutraceutical
Choline magnesium trisalicylateThe risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Acemetacin.Approved
Choline salicylateThe therapeutic efficacy of Acemetacin can be decreased when used in combination with Choline salicylate.Approved, Nutraceutical
CiclesonideThe risk or severity of adverse effects can be increased when Acemetacin is combined with Ciclesonide.Approved, Investigational
CicletanineThe therapeutic efficacy of Cicletanine can be decreased when used in combination with Acemetacin.Investigational
CilazaprilThe therapeutic efficacy of Cilazapril can be decreased when used in combination with Acemetacin.Approved
CinoxacinAcemetacin may increase the neuroexcitatory activities of Cinoxacin.Approved, Investigational, Withdrawn
CiticolineThe therapeutic efficacy of Acemetacin can be decreased when used in combination with Citicoline.Approved, Investigational
Citric AcidThe risk or severity of bleeding can be increased when Citric Acid is combined with Acemetacin.Approved, Nutraceutical, Vet Approved
ClenbuterolThe therapeutic efficacy of Acemetacin can be decreased when used in combination with Clenbuterol.Approved, Investigational, Vet Approved
ClobetasolThe risk or severity of adverse effects can be increased when Acemetacin is combined with Clobetasol.Approved, Investigational
Clobetasol propionateThe risk or severity of adverse effects can be increased when Acemetacin is combined with Clobetasol propionate.Approved
ClobetasoneThe risk or severity of adverse effects can be increased when Acemetacin is combined with Clobetasone.Approved
ClocortoloneThe risk or severity of adverse effects can be increased when Acemetacin is combined with Clocortolone.Approved
Clodronic AcidThe risk or severity of adverse effects can be increased when Acemetacin is combined with Clodronic Acid.Approved, Investigational, Vet Approved
ClofenamideThe therapeutic efficacy of Clofenamide can be decreased when used in combination with Acemetacin.Experimental
ClonidineThe therapeutic efficacy of Clonidine can be decreased when used in combination with Acemetacin.Approved
ClonixinThe risk or severity of adverse effects can be increased when Clonixin is combined with Acemetacin.Approved
ClopamideThe therapeutic efficacy of Clopamide can be decreased when used in combination with Acemetacin.Experimental
CloprostenolThe therapeutic efficacy of Cloprostenol can be decreased when used in combination with Acemetacin.Vet Approved
CloranololThe therapeutic efficacy of Cloranolol can be decreased when used in combination with Acemetacin.Experimental
ClorexoloneThe therapeutic efficacy of Clorexolone can be decreased when used in combination with Acemetacin.Experimental
ColesevelamColesevelam can cause a decrease in the absorption of Acemetacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Acemetacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ConivaptanThe therapeutic efficacy of Conivaptan can be decreased when used in combination with Acemetacin.Approved, Investigational
Cortexolone 17α-propionateThe risk or severity of adverse effects can be increased when Acemetacin is combined with Cortexolone 17α-propionate.Investigational
CorticosteroneThe risk or severity of adverse effects can be increased when Acemetacin is combined with Corticosterone.Experimental
Cortisone acetateThe risk or severity of adverse effects can be increased when Acemetacin is combined with Cortisone acetate.Approved, Investigational
CryptenamineThe therapeutic efficacy of Cryptenamine can be decreased when used in combination with Acemetacin.Approved
CurcuminThe risk or severity of adverse effects can be increased when Curcumin is combined with Acemetacin.Approved, Investigational
CyclopenthiazideThe therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Acemetacin.Experimental
CyclosporineThe risk or severity of renal failure can be increased when Acemetacin is combined with Cyclosporine.Approved, Investigational, Vet Approved
CyclothiazideThe therapeutic efficacy of Cyclothiazide can be decreased when used in combination with Acemetacin.Approved
Dabigatran etexilateThe risk or severity of bleeding can be increased when Dabigatran etexilate is combined with Acemetacin.Approved
DalteparinThe risk or severity of bleeding can be increased when Dalteparin is combined with Acemetacin.Approved
DanaparoidThe risk or severity of bleeding can be increased when Danaparoid is combined with Acemetacin.Approved, Withdrawn
DarexabanThe risk or severity of bleeding can be increased when Darexaban is combined with Acemetacin.Investigational
DaunorubicinAcemetacin may decrease the excretion rate of Daunorubicin which could result in a higher serum level.Approved
DeanolThe therapeutic efficacy of Acemetacin can be decreased when used in combination with Deanol.Experimental
DebrisoquinThe therapeutic efficacy of Debrisoquin can be decreased when used in combination with Acemetacin.Approved, Investigational
DeferasiroxThe risk or severity of adverse effects can be increased when Acemetacin is combined with Deferasirox.Approved, Investigational
DeflazacortThe risk or severity of adverse effects can be increased when Acemetacin is combined with Deflazacort.Approved, Investigational
DelaprilThe therapeutic efficacy of Delapril can be decreased when used in combination with Acemetacin.Experimental
DeoxyepinephrineThe therapeutic efficacy of Acemetacin can be decreased when used in combination with Deoxyepinephrine.Experimental
DeserpidineThe therapeutic efficacy of Deserpidine can be decreased when used in combination with Acemetacin.Approved
DesirudinThe risk or severity of bleeding can be increased when Desirudin is combined with Acemetacin.Approved
DesmopressinThe risk or severity of adverse effects can be increased when Acemetacin is combined with Desmopressin.Approved
DesonideThe risk or severity of adverse effects can be increased when Acemetacin is combined with Desonide.Approved, Investigational
DesoximetasoneThe risk or severity of adverse effects can be increased when Acemetacin is combined with Desoximetasone.Approved
Desoxycorticosterone acetateThe risk or severity of adverse effects can be increased when Acemetacin is combined with Desoxycorticosterone acetate.Approved
Desoxycorticosterone PivalateThe risk or severity of adverse effects can be increased when Acemetacin is combined with Desoxycorticosterone Pivalate.Experimental, Vet Approved
DexamethasoneThe risk or severity of adverse effects can be increased when Acemetacin is combined with Dexamethasone.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe risk or severity of adverse effects can be increased when Acemetacin is combined with Dexamethasone isonicotinate.Vet Approved
DexketoprofenThe risk or severity of adverse effects can be increased when Dexketoprofen is combined with Acemetacin.Approved, Investigational
DextranThe risk or severity of bleeding can be increased when Dextran is combined with Acemetacin.Approved, Investigational, Vet Approved
DiazoxideThe therapeutic efficacy of Diazoxide can be decreased when used in combination with Acemetacin.Approved
DibekacinAcemetacin may decrease the excretion rate of Dibekacin which could result in a higher serum level.Experimental
Dibotermin alfaThe risk or severity of adverse effects can be increased when Acemetacin is combined with Dibotermin alfa.Approved, Investigational
DichloroisoproterenolThe therapeutic efficacy of Acemetacin can be decreased when used in combination with Dichloroisoproterenol.Investigational
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Acemetacin.Approved, Vet Approved
DicloxacillinAcemetacin may decrease the excretion rate of Dicloxacillin which could result in a higher serum level.Approved, Investigational, Vet Approved
DicoumarolThe risk or severity of bleeding can be increased when Dicoumarol is combined with Acemetacin.Approved
DiethylnorspermineThe therapeutic efficacy of Diethylnorspermine can be decreased when used in combination with Acemetacin.Investigational
DifenpiramideThe risk or severity of adverse effects can be increased when Difenpiramide is combined with Acemetacin.Experimental
DiflorasoneThe risk or severity of adverse effects can be increased when Acemetacin is combined with Diflorasone.Approved
DiflunisalThe serum concentration of Acemetacin can be increased when it is combined with Diflunisal.Approved, Investigational
DifluocortoloneThe risk or severity of adverse effects can be increased when Acemetacin is combined with Difluocortolone.Approved, Investigational, Withdrawn
DifluprednateThe risk or severity of adverse effects can be increased when Acemetacin is combined with Difluprednate.Approved
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Acemetacin.Approved
DihydralazineThe therapeutic efficacy of Dihydralazine can be decreased when used in combination with Acemetacin.Approved, Investigational
DihydrostreptomycinAcemetacin may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Investigational, Vet Approved
DiltiazemThe therapeutic efficacy of Diltiazem can be decreased when used in combination with Acemetacin.Approved, Investigational
DimetofrineThe therapeutic efficacy of Acemetacin can be decreased when used in combination with Dimetofrine.Experimental
DinoprostThe therapeutic efficacy of Dinoprost can be decreased when used in combination with Acemetacin.Investigational
Dinoprost TromethamineThe therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Acemetacin.Approved, Vet Approved
DinoprostoneThe therapeutic efficacy of Dinoprostone can be decreased when used in combination with Acemetacin.Approved
DipivefrinThe therapeutic efficacy of Acemetacin can be decreased when used in combination with Dipivefrin.Approved
DorzolamideThe therapeutic efficacy of Dorzolamide can be decreased when used in combination with Acemetacin.Approved
DoxazosinThe therapeutic efficacy of Doxazosin can be decreased when used in combination with Acemetacin.Approved
DoxorubicinAcemetacin may decrease the excretion rate of Doxorubicin which could result in a higher serum level.Approved, Investigational
DrospirenoneThe therapeutic efficacy of Drospirenone can be decreased when used in combination with Acemetacin.Approved
DroxicamThe risk or severity of adverse effects can be increased when Droxicam is combined with Acemetacin.Withdrawn
DroxidopaThe therapeutic efficacy of Acemetacin can be decreased when used in combination with Droxidopa.Approved, Investigational
DuvelisibThe risk or severity of adverse effects can be increased when Duvelisib is combined with Acemetacin.Investigational
E-6201The risk or severity of adverse effects can be increased when E-6201 is combined with Acemetacin.Investigational
Edetic AcidThe risk or severity of bleeding can be increased when Edetic Acid is combined with Acemetacin.Approved, Vet Approved
EdivoxetineThe therapeutic efficacy of Acemetacin can be decreased when used in combination with Edivoxetine.Investigational
EdoxabanThe risk or severity of bleeding can be increased when Edoxaban is combined with Acemetacin.Approved
EfonidipineThe therapeutic efficacy of Efonidipine can be decreased when used in combination with Acemetacin.Approved, Investigational
EnalaprilThe therapeutic efficacy of Enalapril can be decreased when used in combination with Acemetacin.Approved, Vet Approved
EnalaprilatThe therapeutic efficacy of Enalaprilat can be decreased when used in combination with Acemetacin.Approved
EndralazineThe therapeutic efficacy of Endralazine can be decreased when used in combination with Acemetacin.Experimental
EnoxacinAcemetacin may increase the neuroexcitatory activities of Enoxacin.Approved, Investigational
EnoxaparinThe risk or severity of bleeding can be increased when Enoxaparin is combined with Acemetacin.Approved
EnprostilThe therapeutic efficacy of Enprostil can be decreased when used in combination with Acemetacin.Experimental
EpanololThe therapeutic efficacy of Epanolol can be decreased when used in combination with Acemetacin.Experimental
EpinephrineThe therapeutic efficacy of Acemetacin can be decreased when used in combination with Epinephrine.Approved, Vet Approved
EpirizoleThe risk or severity of adverse effects can be increased when Epirizole is combined with Acemetacin.Approved
EpirubicinAcemetacin may decrease the excretion rate of Epirubicin which could result in a higher serum level.Approved
EpitizideThe therapeutic efficacy of Epitizide can be decreased when used in combination with Acemetacin.Experimental
EplerenoneThe therapeutic efficacy of Eplerenone can be decreased when used in combination with Acemetacin.Approved
EpoprostenolThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Acemetacin.Approved
EprosartanThe therapeutic efficacy of Eprosartan can be decreased when used in combination with Acemetacin.Approved
EquileninThe risk or severity of adverse effects can be increased when Acemetacin is combined with Equilenin.Experimental
EquilinThe risk or severity of adverse effects can be increased when Acemetacin is combined with Equilin.Approved
EsmololAcemetacin may decrease the antihypertensive activities of Esmolol.Approved
EstroneThe risk or severity of adverse effects can be increased when Acemetacin is combined with Estrone.Approved
Estrone sulfateThe risk or severity of adverse effects can be increased when Acemetacin is combined with Estrone sulfate.Approved
Etacrynic acidThe therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Acemetacin.Approved, Investigational
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with Acemetacin.Approved, Investigational
EthanolamineThe therapeutic efficacy of Acemetacin can be decreased when used in combination with Ethanolamine.Experimental
EthenzamideThe risk or severity of adverse effects can be increased when Ethenzamide is combined with Acemetacin.Experimental
EthoxzolamideThe therapeutic efficacy of Ethoxzolamide can be decreased when used in combination with Acemetacin.Withdrawn
Ethyl biscoumacetateThe risk or severity of bleeding can be increased when Ethyl biscoumacetate is combined with Acemetacin.Withdrawn
Etidronic acidThe risk or severity of adverse effects can be increased when Acemetacin is combined with Etidronic acid.Approved
EtilefrineThe therapeutic efficacy of Acemetacin can be decreased when used in combination with Etilefrine.Withdrawn
EtodolacThe risk or severity of adverse effects can be increased when Etodolac is combined with Acemetacin.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Etofenamate is combined with Acemetacin.Approved, Investigational
EtoricoxibThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Acemetacin.Approved, Investigational
Evening primrose oilThe risk or severity of adverse effects can be increased when Evening primrose oil is combined with Acemetacin.Approved, Investigational
ExisulindThe risk or severity of adverse effects can be increased when Exisulind is combined with Acemetacin.Investigational
FelbinacThe risk or severity of adverse effects can be increased when Felbinac is combined with Acemetacin.Experimental
FelodipineThe therapeutic efficacy of Felodipine can be decreased when used in combination with Acemetacin.Approved, Investigational
FenbufenThe risk or severity of adverse effects can be increased when Fenbufen is combined with Acemetacin.Approved
FenoldopamThe therapeutic efficacy of Fenoldopam can be decreased when used in combination with Acemetacin.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Acemetacin.Approved
FenoterolThe therapeutic efficacy of Acemetacin can be decreased when used in combination with Fenoterol.Approved, Investigational
FenprostaleneThe therapeutic efficacy of Fenprostalene can be decreased when used in combination with Acemetacin.Vet Approved
FenquizoneThe therapeutic efficacy of Fenquizone can be decreased when used in combination with Acemetacin.Experimental
FentiazacThe risk or severity of adverse effects can be increased when Fentiazac is combined with Acemetacin.Experimental
FeprazoneThe risk or severity of adverse effects can be increased when Feprazone is combined with Acemetacin.Experimental
Ferulic acidThe risk or severity of adverse effects can be increased when Ferulic acid is combined with Acemetacin.Experimental
FimasartanThe risk or severity of adverse effects can be increased when Fimasartan is combined with Acemetacin.Approved, Investigational
FleroxacinAcemetacin may increase the neuroexcitatory activities of Fleroxacin.Approved
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Acemetacin.Approved, Withdrawn
FluasteroneThe risk or severity of adverse effects can be increased when Acemetacin is combined with Fluasterone.Investigational
FludrocortisoneThe risk or severity of adverse effects can be increased when Acemetacin is combined with Fludrocortisone.Approved, Investigational
FluindioneThe risk or severity of bleeding can be increased when Fluindione is combined with Acemetacin.Approved, Investigational
FlumequineAcemetacin may increase the neuroexcitatory activities of Flumequine.Withdrawn
FlumethasoneThe risk or severity of adverse effects can be increased when Acemetacin is combined with Flumethasone.Approved, Vet Approved
FlunisolideThe risk or severity of adverse effects can be increased when Acemetacin is combined with Flunisolide.Approved, Investigational
FlunixinThe risk or severity of adverse effects can be increased when Flunixin is combined with Acemetacin.Vet Approved
FlunoxaprofenThe risk or severity of adverse effects can be increased when Flunoxaprofen is combined with Acemetacin.Experimental
Fluocinolone AcetonideThe risk or severity of adverse effects can be increased when Acemetacin is combined with Fluocinolone Acetonide.Approved, Investigational, Vet Approved
FluocinonideThe risk or severity of adverse effects can be increased when Acemetacin is combined with Fluocinonide.Approved, Investigational
FluocortoloneThe risk or severity of adverse effects can be increased when Acemetacin is combined with Fluocortolone.Approved, Withdrawn
FluorometholoneThe risk or severity of adverse effects can be increased when Acemetacin is combined with Fluorometholone.Approved, Investigational
FluprednideneThe risk or severity of adverse effects can be increased when Acemetacin is combined with Fluprednidene.Approved, Withdrawn
FluprednisoloneThe risk or severity of adverse effects can be increased when Acemetacin is combined with Fluprednisolone.Approved
FluprostenolThe therapeutic efficacy of Fluprostenol can be decreased when used in combination with Acemetacin.Vet Approved
FlurandrenolideThe risk or severity of adverse effects can be increased when Acemetacin is combined with Flurandrenolide.Approved
FlurbiprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Acemetacin.Approved, Investigational
Fluticasone furoateThe risk or severity of adverse effects can be increased when Acemetacin is combined with Fluticasone furoate.Approved
Fluticasone propionateThe risk or severity of adverse effects can be increased when Acemetacin is combined with Fluticasone propionate.Approved
Folic AcidThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Acemetacin.Approved, Nutraceutical, Vet Approved
FondaparinuxThe risk or severity of bleeding can be increased when Fondaparinux is combined with Acemetacin.Approved, Investigational
Fondaparinux sodiumThe risk or severity of bleeding can be increased when Fondaparinux sodium is combined with Acemetacin.Approved, Investigational
ForasartanThe risk or severity of adverse effects can be increased when Forasartan is combined with Acemetacin.Experimental
FormestaneThe risk or severity of adverse effects can be increased when Acemetacin is combined with Formestane.Approved, Investigational, Withdrawn
FormoterolThe therapeutic efficacy of Acemetacin can be decreased when used in combination with Formoterol.Approved, Investigational
FosinoprilThe therapeutic efficacy of Fosinopril can be decreased when used in combination with Acemetacin.Approved
FramycetinAcemetacin may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved
FurosemideFurosemide may increase the excretion rate of Acemetacin which could result in a lower serum level and potentially a reduction in efficacy.Approved, Vet Approved
GabexateThe risk or severity of bleeding can be increased when Gabexate is combined with Acemetacin.Investigational
GarenoxacinAcemetacin may increase the neuroexcitatory activities of Garenoxacin.Investigational
GatifloxacinAcemetacin may increase the neuroexcitatory activities of Gatifloxacin.Approved, Investigational
GemeprostThe therapeutic efficacy of Gemeprost can be decreased when used in combination with Acemetacin.Approved, Withdrawn
GemifloxacinAcemetacin may increase the neuroexcitatory activities of Gemifloxacin.Approved, Investigational
GeneticinAcemetacin may decrease the excretion rate of Geneticin which could result in a higher serum level.Experimental
GentamicinAcemetacin may decrease the excretion rate of Gentamicin which could result in a higher serum level.Approved, Vet Approved
GENTAMICIN C1AAcemetacin may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Experimental
GPX-150Acemetacin may decrease the excretion rate of GPX-150 which could result in a higher serum level.Investigational
GrepafloxacinAcemetacin may increase the neuroexcitatory activities of Grepafloxacin.Approved, Investigational, Withdrawn
GuacetisalThe risk or severity of adverse effects can be increased when Guacetisal is combined with Acemetacin.Experimental
GuanabenzThe therapeutic efficacy of Guanabenz can be decreased when used in combination with Acemetacin.Approved, Investigational
GuanadrelThe therapeutic efficacy of Guanadrel can be decreased when used in combination with Acemetacin.Approved
GuanazodineThe therapeutic efficacy of Guanazodine can be decreased when used in combination with Acemetacin.Experimental
GuanethidineThe therapeutic efficacy of Guanethidine can be decreased when used in combination with Acemetacin.Approved
GuanfacineThe therapeutic efficacy of Guanfacine can be decreased when used in combination with Acemetacin.Approved, Investigational
GuanoclorThe therapeutic efficacy of Guanoclor can be decreased when used in combination with Acemetacin.Experimental
GuanoxabenzThe therapeutic efficacy of Guanoxabenz can be decreased when used in combination with Acemetacin.Experimental
GuanoxanThe therapeutic efficacy of Guanoxan can be decreased when used in combination with Acemetacin.Experimental
HalcinonideThe risk or severity of adverse effects can be increased when Acemetacin is combined with Halcinonide.Approved, Investigational, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Acemetacin is combined with Haloperidol.Approved
HE3286The risk or severity of adverse effects can be increased when Acemetacin is combined with HE3286.Investigational
HeparinThe risk or severity of bleeding can be increased when Heparin is combined with Acemetacin.Approved, Investigational
HexamethoniumThe therapeutic efficacy of Hexamethonium can be decreased when used in combination with Acemetacin.Experimental
HigenamineThe risk or severity of adverse effects can be increased when Higenamine is combined with Acemetacin.Investigational
HydralazineThe therapeutic efficacy of Hydralazine can be decreased when used in combination with Acemetacin.Approved
HydrochlorothiazideThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Acemetacin.Approved, Vet Approved
HydrocortisoneThe risk or severity of adverse effects can be increased when Acemetacin is combined with Hydrocortisone.Approved, Vet Approved
HydroflumethiazideThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Acemetacin.Approved, Investigational
HydroxytyrosolThe therapeutic efficacy of Acemetacin can be decreased when used in combination with Hydroxytyrosol.Investigational
Hygromycin BAcemetacin may decrease the excretion rate of Hygromycin B which could result in a higher serum level.Vet Approved
IbandronateThe risk or severity of adverse effects can be increased when Acemetacin is combined with Ibandronate.Approved, Investigational
IbopamineThe therapeutic efficacy of Ibopamine can be decreased when used in combination with Acemetacin.Experimental
IbuprofenThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Acemetacin.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Ibuproxam is combined with Acemetacin.Withdrawn
IcatibantThe risk or severity of adverse effects can be increased when Icatibant is combined with Acemetacin.Approved, Investigational
IdarubicinAcemetacin may decrease the excretion rate of Idarubicin which could result in a higher serum level.Approved
IdraparinuxThe risk or severity of bleeding can be increased when Idraparinux is combined with Acemetacin.Investigational
IdrocilamideThe therapeutic efficacy of Acemetacin can be decreased when used in combination with Idrocilamide.Experimental
IloprostThe therapeutic efficacy of Iloprost can be decreased when used in combination with Acemetacin.Approved, Investigational
ImidaprilThe therapeutic efficacy of Imidapril can be decreased when used in combination with Acemetacin.Investigational
Imidazole salicylateThe risk or severity of adverse effects can be increased when Imidazole salicylate is combined with Acemetacin.Experimental
IndapamideThe therapeutic efficacy of Indapamide can be decreased when used in combination with Acemetacin.Approved
IndenololThe therapeutic efficacy of Indenolol can be decreased when used in combination with Acemetacin.Withdrawn
IndobufenThe risk or severity of adverse effects can be increased when Indobufen is combined with Acemetacin.Investigational
IndomethacinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Acemetacin.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Indoprofen is combined with Acemetacin.Withdrawn
IndoraminThe therapeutic efficacy of Indoramin can be decreased when used in combination with Acemetacin.Withdrawn
IrbesartanThe therapeutic efficacy of Irbesartan can be decreased when used in combination with Acemetacin.Approved, Investigational
IsepamicinAcemetacin may decrease the excretion rate of Isepamicin which could result in a higher serum level.Experimental
IsoprenalineThe therapeutic efficacy of Acemetacin can be decreased when used in combination with Isoprenaline.Approved, Investigational
IsosorbideThe therapeutic efficacy of Isosorbide can be decreased when used in combination with Acemetacin.Approved, Investigational
IsoxicamThe risk or severity of adverse effects can be increased when Isoxicam is combined with Acemetacin.Withdrawn
IsradipineThe therapeutic efficacy of Isradipine can be decreased when used in combination with Acemetacin.Approved, Investigational
IstaroximeThe risk or severity of adverse effects can be increased when Acemetacin is combined with Istaroxime.Investigational
KanamycinAcemetacin may decrease the excretion rate of Kanamycin which could result in a higher serum level.Approved, Investigational, Vet Approved
KebuzoneThe risk or severity of adverse effects can be increased when Kebuzone is combined with Acemetacin.Experimental
KetanserinThe therapeutic efficacy of Ketanserin can be decreased when used in combination with Acemetacin.Investigational
KetoprofenThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Acemetacin.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Acemetacin.Approved
LabetalolThe therapeutic efficacy of Labetalol can be decreased when used in combination with Acemetacin.Approved
LacidipineThe therapeutic efficacy of Lacidipine can be decreased when used in combination with Acemetacin.Approved, Investigational
LandiololAcemetacin may decrease the antihypertensive activities of Landiolol.Investigational
LatanoprostThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Acemetacin.Approved, Investigational
Latanoprostene BunodThe therapeutic efficacy of Latanoprostene Bunod can be decreased when used in combination with Acemetacin.Approved, Investigational
LeflunomideThe risk or severity of adverse effects can be increased when Leflunomide is combined with Acemetacin.Approved, Investigational
LepirudinThe risk or severity of bleeding can be increased when Lepirudin is combined with Acemetacin.Approved
LercanidipineThe therapeutic efficacy of Lercanidipine can be decreased when used in combination with Acemetacin.Approved, Investigational
LetaxabanThe risk or severity of bleeding can be increased when Letaxaban is combined with Acemetacin.Investigational
LevobunololAcemetacin may decrease the antihypertensive activities of Levobunolol.Approved
LevofloxacinAcemetacin may increase the neuroexcitatory activities of Levofloxacin.Approved, Investigational
LevonordefrinThe therapeutic efficacy of Acemetacin can be decreased when used in combination with Levonordefrin.Approved
LimaprostThe therapeutic efficacy of Limaprost can be decreased when used in combination with Acemetacin.Approved, Investigational
LinsidomineThe therapeutic efficacy of Linsidomine can be decreased when used in combination with Acemetacin.Experimental
LisinoprilThe therapeutic efficacy of Lisinopril can be decreased when used in combination with Acemetacin.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Lisofylline is combined with Acemetacin.Investigational
LithiumThe serum concentration of Lithium can be increased when it is combined with Acemetacin.Approved
LofexidineThe therapeutic efficacy of Lofexidine can be decreased when used in combination with Acemetacin.Approved, Investigational
LonazolacThe risk or severity of adverse effects can be increased when Lonazolac is combined with Acemetacin.Experimental
LornoxicamThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Acemetacin.Approved, Investigational
LosartanThe therapeutic efficacy of Losartan can be decreased when used in combination with Acemetacin.Approved
LoteprednolThe risk or severity of adverse effects can be increased when Acemetacin is combined with Loteprednol.Approved
LoxoprofenThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Acemetacin.Approved, Investigational
LubiprostoneThe therapeutic efficacy of Lubiprostone can be decreased when used in combination with Acemetacin.Approved, Investigational
LumefantrineThe therapeutic efficacy of Acemetacin can be decreased when used in combination with Lumefantrine.Approved
LumiracoxibThe risk or severity of adverse effects can be increased when Lumiracoxib is combined with Acemetacin.Approved, Investigational
LuprostiolThe therapeutic efficacy of Luprostiol can be decreased when used in combination with Acemetacin.Vet Approved
MacitentanThe therapeutic efficacy of Macitentan can be decreased when used in combination with Acemetacin.Approved
Magnesium salicylateThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Acemetacin.Approved
ManidipineThe therapeutic efficacy of Manidipine can be decreased when used in combination with Acemetacin.Approved, Investigational
MannitolThe therapeutic efficacy of Mannitol can be decreased when used in combination with Acemetacin.Approved, Investigational
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Acemetacin.Approved, Investigational
ME-609The risk or severity of adverse effects can be increased when Acemetacin is combined with ME-609.Investigational
MebutizideThe therapeutic efficacy of Mebutizide can be decreased when used in combination with Acemetacin.Experimental
MecamylamineThe therapeutic efficacy of Mecamylamine can be decreased when used in combination with Acemetacin.Approved, Investigational
Meclofenamic acidThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Acemetacin.Approved, Vet Approved
MedrysoneThe risk or severity of adverse effects can be increased when Acemetacin is combined with Medrysone.Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Acemetacin.Approved
MefrusideThe therapeutic efficacy of Mefruside can be decreased when used in combination with Acemetacin.Experimental
MelagatranThe risk or severity of bleeding can be increased when Melagatran is combined with Acemetacin.Experimental
MelengestrolThe risk or severity of adverse effects can be increased when Acemetacin is combined with Melengestrol.Vet Approved
MeloxicamThe risk or severity of adverse effects can be increased when Meloxicam is combined with Acemetacin.Approved, Vet Approved
MepindololAcemetacin may decrease the antihypertensive activities of Mepindolol.Experimental
MersalylThe therapeutic efficacy of Mersalyl can be decreased when used in combination with Acemetacin.Approved
MesalazineThe risk or severity of adverse effects can be increased when Mesalazine is combined with Acemetacin.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Acemetacin.Approved, Investigational, Withdrawn
MethazolamideThe therapeutic efficacy of Methazolamide can be decreased when used in combination with Acemetacin.Approved
MethoserpidineThe therapeutic efficacy of Methoserpidine can be decreased when used in combination with Acemetacin.Experimental
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Acemetacin.Approved
MethyclothiazideThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Acemetacin.Approved
MethyldopaThe therapeutic efficacy of Methyldopa can be decreased when used in combination with Acemetacin.Approved
MethylprednisoloneThe risk or severity of adverse effects can be increased when Acemetacin is combined with Methylprednisolone.Approved, Vet Approved
MeticraneThe therapeutic efficacy of Meticrane can be decreased when used in combination with Acemetacin.Experimental
MetipranololThe therapeutic efficacy of Metipranolol can be decreased when used in combination with Acemetacin.Approved
MetolazoneThe therapeutic efficacy of Metolazone can be decreased when used in combination with Acemetacin.Approved
MetoprololThe therapeutic efficacy of Metoprolol can be decreased when used in combination with Acemetacin.Approved, Investigational
MetrizamideAcemetacin may decrease the excretion rate of Metrizamide which could result in a higher serum level.Approved
MetyrosineThe therapeutic efficacy of Metyrosine can be decreased when used in combination with Acemetacin.Approved
MibefradilThe therapeutic efficacy of Mibefradil can be decreased when used in combination with Acemetacin.Investigational, Withdrawn
MicronomicinAcemetacin may decrease the excretion rate of Micronomicin which could result in a higher serum level.Experimental
MidodrineThe therapeutic efficacy of Acemetacin can be decreased when used in combination with Midodrine.Approved
MifamurtideThe therapeutic efficacy of Mifamurtide can be decreased when used in combination with Acemetacin.Approved, Experimental
MiltefosineThe therapeutic efficacy of Acemetacin can be decreased when used in combination with Miltefosine.Approved, Investigational
MinoxidilThe therapeutic efficacy of Minoxidil can be decreased when used in combination with Acemetacin.Approved, Investigational
MisoprostolThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Acemetacin.Approved
MizoribineThe risk or severity of adverse effects can be increased when Mizoribine is combined with Acemetacin.Investigational
MoexiprilThe therapeutic efficacy of Moexipril can be decreased when used in combination with Acemetacin.Approved
MofebutazoneThe risk or severity of adverse effects can be increased when Mofebutazone is combined with Acemetacin.Experimental
MometasoneThe risk or severity of adverse effects can be increased when Acemetacin is combined with Mometasone.Approved, Vet Approved
MorniflumateThe risk or severity of adverse effects can be increased when Morniflumate is combined with Acemetacin.Approved
MoxonidineThe therapeutic efficacy of Moxonidine can be decreased when used in combination with Acemetacin.Approved, Investigational
MuzolimineThe therapeutic efficacy of Muzolimine can be decreased when used in combination with Acemetacin.Experimental
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Acemetacin.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Acemetacin.Approved
N,N,N-Trimethyl-2-(phosphonooxy)ethanaminiumThe therapeutic efficacy of Acemetacin can be decreased when used in combination with N,N,N-Trimethyl-2-(phosphonooxy)ethanaminium.Experimental
NabumetoneThe risk or severity of adverse effects can be increased when Nabumetone is combined with Acemetacin.Approved
NadololThe therapeutic efficacy of Nadolol can be decreased when used in combination with Acemetacin.Approved
NadroparinThe risk or severity of bleeding can be increased when Nadroparin is combined with Acemetacin.Approved, Investigational
NafamostatThe risk or severity of adverse effects can be increased when Nafamostat is combined with Acemetacin.Approved, Investigational
NafcillinAcemetacin may decrease the excretion rate of Nafcillin which could result in a higher serum level.Approved, Investigational
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Acemetacin.Approved
NaftopidilThe therapeutic efficacy of Naftopidil can be decreased when used in combination with Acemetacin.Investigational
Nalidixic AcidAcemetacin may increase the neuroexcitatory activities of Nalidixic Acid.Approved, Investigational
NaproxenThe risk or severity of adverse effects can be increased when Naproxen is combined with Acemetacin.Approved, Vet Approved
NCX 1022The risk or severity of adverse effects can be increased when Acemetacin is combined with NCX 1022.Investigational
NeamineAcemetacin may decrease the excretion rate of Neamine which could result in a higher serum level.Experimental
NebivololThe therapeutic efficacy of Nebivolol can be decreased when used in combination with Acemetacin.Approved, Investigational
NemonoxacinAcemetacin may increase the neuroexcitatory activities of Nemonoxacin.Investigational
NeomycinAcemetacin may decrease the excretion rate of Neomycin which could result in a higher serum level.Approved, Vet Approved
NepafenacThe risk or severity of adverse effects can be increased when Nepafenac is combined with Acemetacin.Approved, Investigational
NetilmicinAcemetacin may decrease the excretion rate of Netilmicin which could result in a higher serum level.Approved, Investigational
NicardipineThe therapeutic efficacy of Nicardipine can be decreased when used in combination with Acemetacin.Approved, Investigational
NicorandilThe therapeutic efficacy of Nicorandil can be decreased when used in combination with Acemetacin.Approved, Investigational
NifenazoneThe risk or severity of adverse effects can be increased when Nifenazone is combined with Acemetacin.Experimental
Niflumic AcidThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Acemetacin.Approved
NiguldipineThe therapeutic efficacy of Niguldipine can be decreased when used in combination with Acemetacin.Experimental
NilvadipineThe therapeutic efficacy of Nilvadipine can be decreased when used in combination with Acemetacin.Approved, Investigational
NimesulideThe risk or severity of adverse effects can be increased when Nimesulide is combined with Acemetacin.Approved, Investigational, Withdrawn
NimodipineThe therapeutic efficacy of Nimodipine can be decreased when used in combination with Acemetacin.Approved, Investigational
NisoldipineThe therapeutic efficacy of Nisoldipine can be decreased when used in combination with Acemetacin.Approved
NitrendipineThe therapeutic efficacy of Nitrendipine can be decreased when used in combination with Acemetacin.Approved, Investigational
NitroaspirinThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Acemetacin.Investigational
NitroprussideThe therapeutic efficacy of Nitroprusside can be decreased when used in combination with Acemetacin.Approved, Investigational
NorepinephrineThe therapeutic efficacy of Acemetacin can be decreased when used in combination with Norepinephrine.Approved
NorfenefrineThe therapeutic efficacy of Acemetacin can be decreased when used in combination with Norfenefrine.Experimental
NorfloxacinAcemetacin may increase the neuroexcitatory activities of Norfloxacin.Approved
OctopamineThe therapeutic efficacy of Acemetacin can be decreased when used in combination with Octopamine.Experimental
Oleoyl-estroneThe risk or severity of adverse effects can be increased when Acemetacin is combined with Oleoyl-estrone.Investigational
OlmesartanThe therapeutic efficacy of Olmesartan can be decreased when used in combination with Acemetacin.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Acemetacin.Approved
OlsalazineThe risk or severity of adverse effects can be increased when Olsalazine is combined with Acemetacin.Approved
Omacetaxine mepesuccinateThe risk or severity of bleeding can be increased when Acemetacin is combined with Omacetaxine mepesuccinate.Approved, Investigational
OmapatrilatThe therapeutic efficacy of Omapatrilat can be decreased when used in combination with Acemetacin.Investigational
OrciprenalineThe therapeutic efficacy of Acemetacin can be decreased when used in combination with Orciprenaline.Approved
OrgoteinThe risk or severity of adverse effects can be increased when Orgotein is combined with Acemetacin.Vet Approved
OtamixabanThe risk or severity of bleeding can be increased when Otamixaban is combined with Acemetacin.Investigational
OxacillinAcemetacin may decrease the excretion rate of Oxacillin which could result in a higher serum level.Approved, Investigational
OxaprozinThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Acemetacin.Approved
OxethazaineThe therapeutic efficacy of Acemetacin can be decreased when used in combination with Oxethazaine.Approved, Investigational
OxilofrineThe therapeutic efficacy of Acemetacin can be decreased when used in combination with Oxilofrine.Approved
Oxolinic acidAcemetacin may increase the neuroexcitatory activities of Oxolinic acid.Experimental
OxprenololThe therapeutic efficacy of Oxprenolol can be decreased when used in combination with Acemetacin.Approved
OxtriphyllineThe therapeutic efficacy of Acemetacin can be decreased when used in combination with Oxtriphylline.Approved
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Acemetacin.Approved, Withdrawn
PamabromThe therapeutic efficacy of Pamabrom can be decreased when used in combination with Acemetacin.Approved
PamidronateThe risk or severity of adverse effects can be increased when Acemetacin is combined with Pamidronate.Approved
ParamethasoneThe risk or severity of adverse effects can be increased when Acemetacin is combined with Paramethasone.Approved
ParecoxibThe risk or severity of adverse effects can be increased when Parecoxib is combined with Acemetacin.Approved
PargylineThe therapeutic efficacy of Pargyline can be decreased when used in combination with Acemetacin.Approved
ParomomycinAcemetacin may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved, Investigational
ParthenolideThe risk or severity of adverse effects can be increased when Parthenolide is combined with Acemetacin.Approved, Investigational
PazufloxacinAcemetacin may increase the neuroexcitatory activities of Pazufloxacin.Investigational
PefloxacinAcemetacin may increase the neuroexcitatory activities of Pefloxacin.Approved
PenbutololThe therapeutic efficacy of Penbutolol can be decreased when used in combination with Acemetacin.Approved, Investigational
Pentaerythritol TetranitrateThe risk or severity of bleeding can be increased when Pentaerythritol Tetranitrate is combined with Acemetacin.Approved
PentoliniumThe therapeutic efficacy of Pentolinium can be decreased when used in combination with Acemetacin.Approved
Pentosan PolysulfateThe risk or severity of bleeding can be increased when Pentosan Polysulfate is combined with Acemetacin.Approved
PerifosineThe therapeutic efficacy of Acemetacin can be decreased when used in combination with Perifosine.Investigational
PerindoprilThe therapeutic efficacy of Perindopril can be decreased when used in combination with Acemetacin.Approved
PhenindioneThe risk or severity of bleeding can be increased when Phenindione is combined with Acemetacin.Approved, Investigational
PhenoxybenzamineThe therapeutic efficacy of Phenoxybenzamine can be decreased when used in combination with Acemetacin.Approved
PhenoxymethylpenicillinAcemetacin may decrease the excretion rate of Phenoxymethylpenicillin which could result in a higher serum level.Approved, Vet Approved
PhenprocoumonThe risk or severity of bleeding can be increased when Phenprocoumon is combined with Acemetacin.Approved, Investigational
PhentolamineThe therapeutic efficacy of Phentolamine can be decreased when used in combination with Acemetacin.Approved
PhenylbutazoneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Acemetacin.Approved, Vet Approved
PhenylephrineThe therapeutic efficacy of Acemetacin can be decreased when used in combination with Phenylephrine.Approved
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Acemetacin.Approved, Vet Approved
PhosphorylcolamineThe therapeutic efficacy of Acemetacin can be decreased when used in combination with Phosphorylcolamine.Experimental
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Acemetacin.Approved, Investigational
PinacidilThe therapeutic efficacy of Pinacidil can be decreased when used in combination with Acemetacin.Approved
PindololThe therapeutic efficacy of Pindolol can be decreased when used in combination with Acemetacin.Approved, Investigational
Pipemidic acidAcemetacin may increase the neuroexcitatory activities of Pipemidic acid.Experimental
PirarubicinAcemetacin may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Investigational
PirbuterolThe therapeutic efficacy of Acemetacin can be decreased when used in combination with Pirbuterol.Approved
PiretanideThe therapeutic efficacy of Piretanide can be decreased when used in combination with Acemetacin.Approved
PirfenidoneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Acemetacin.Approved, Investigational
Piromidic acidAcemetacin may increase the neuroexcitatory activities of Piromidic acid.Experimental
PiroxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with Acemetacin.Approved, Investigational
PirprofenThe risk or severity of adverse effects can be increased when Pirprofen is combined with Acemetacin.Experimental
PitolisantThe risk or severity of adverse effects can be increased when Acemetacin is combined with Pitolisant.Approved, Investigational
Platelet Activating FactorThe therapeutic efficacy of Platelet Activating Factor can be decreased when used in combination with Acemetacin.Experimental
PlazomicinAcemetacin may decrease the excretion rate of Plazomicin which could result in a higher serum level.Investigational
PlicamycinAcemetacin may decrease the excretion rate of Plicamycin which could result in a higher serum level.Approved, Investigational, Withdrawn
PolythiazideThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Acemetacin.Approved
PotassiumThe therapeutic efficacy of Potassium can be decreased when used in combination with Acemetacin.Approved, Investigational
Potassium CitrateThe therapeutic efficacy of Potassium Citrate can be decreased when used in combination with Acemetacin.Approved, Investigational, Vet Approved
PractololAcemetacin may decrease the antihypertensive activities of Practolol.Approved
PralatrexateThe serum concentration of Pralatrexate can be increased when it is combined with Acemetacin.Approved, Investigational
PranoprofenThe risk or severity of adverse effects can be increased when Pranoprofen is combined with Acemetacin.Experimental, Investigational
PrasteroneThe risk or severity of adverse effects can be increased when Acemetacin is combined with Prasterone.Approved, Investigational, Nutraceutical
Prasterone sulfateThe risk or severity of adverse effects can be increased when Acemetacin is combined with Prasterone sulfate.Investigational
PrazosinThe therapeutic efficacy of Prazosin can be decreased when used in combination with Acemetacin.Approved
PrednicarbateThe risk or severity of adverse effects can be increased when Acemetacin is combined with Prednicarbate.Approved, Investigational
PrednisoloneThe risk or severity of adverse effects can be increased when Acemetacin is combined with Prednisolone.Approved, Vet Approved
PrednisoneThe risk or severity of adverse effects can be increased when Acemetacin is combined with Prednisone.Approved, Vet Approved
PregnenoloneThe risk or severity of adverse effects can be increased when Acemetacin is combined with Pregnenolone.Approved, Experimental, Investigational
ProbenecidThe serum concentration of Acemetacin can be increased when it is combined with Probenecid.Approved, Investigational
Procaine benzylpenicillinAcemetacin may decrease the excretion rate of Procaine benzylpenicillin which could result in a higher serum level.Approved, Vet Approved
ProcaterolThe therapeutic efficacy of Acemetacin can be decreased when used in combination with Procaterol.Approved, Investigational
ProglumetacinThe risk or severity of adverse effects can be increased when Proglumetacin is combined with Acemetacin.Experimental
PropacetamolThe risk or severity of adverse effects can be increased when Propacetamol is combined with Acemetacin.Approved, Investigational
PropranololThe therapeutic efficacy of Propranolol can be decreased when used in combination with Acemetacin.Approved, Investigational
PropyphenazoneThe risk or severity of adverse effects can be increased when Propyphenazone is combined with Acemetacin.Experimental
ProquazoneThe risk or severity of adverse effects can be increased when Proquazone is combined with Acemetacin.Experimental
Prostaglandin B2The therapeutic efficacy of Prostaglandin B2 can be decreased when used in combination with Acemetacin.Experimental
Prostaglandin G2The therapeutic efficacy of Prostaglandin G2 can be decreased when used in combination with Acemetacin.Experimental
ProstaleneThe therapeutic efficacy of Prostalene can be decreased when used in combination with Acemetacin.Vet Approved
Protein CThe risk or severity of bleeding can be increased when Protein C is combined with Acemetacin.Approved
Protein S humanThe risk or severity of bleeding can be increased when Protein S human is combined with Acemetacin.Approved
ProtocatechualdehydeThe risk or severity of bleeding can be increased when Protocatechualdehyde is combined with Acemetacin.Approved
ProtokylolThe therapeutic efficacy of Acemetacin can be decreased when used in combination with Protokylol.Approved, Vet Approved
PrulifloxacinAcemetacin may increase the neuroexcitatory activities of Prulifloxacin.Investigational
PTC299The risk or severity of adverse effects can be increased when PTC299 is combined with Acemetacin.Investigational
PuromycinAcemetacin may decrease the excretion rate of Puromycin which could result in a higher serum level.Experimental
QuinaprilThe therapeutic efficacy of Quinapril can be decreased when used in combination with Acemetacin.Approved, Investigational
QuinethazoneThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Acemetacin.Approved
RacepinephrineThe therapeutic efficacy of Acemetacin can be decreased when used in combination with Racepinephrine.Approved
RamiprilThe therapeutic efficacy of Ramipril can be decreased when used in combination with Acemetacin.Approved
RemikirenThe therapeutic efficacy of Remikiren can be decreased when used in combination with Acemetacin.Approved
ReproterolThe therapeutic efficacy of Acemetacin can be decreased when used in combination with Reproterol.Investigational
RescinnamineThe therapeutic efficacy of Rescinnamine can be decreased when used in combination with Acemetacin.Approved
ReserpineThe therapeutic efficacy of Reserpine can be decreased when used in combination with Acemetacin.Approved, Investigational
ResveratrolThe risk or severity of adverse effects can be increased when Resveratrol is combined with Acemetacin.Approved, Experimental, Investigational
ReviparinThe risk or severity of bleeding can be increased when Reviparin is combined with Acemetacin.Approved, Investigational
RibostamycinAcemetacin may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved, Investigational
RilmenidineThe therapeutic efficacy of Rilmenidine can be decreased when used in combination with Acemetacin.Approved, Investigational
RimexoloneThe risk or severity of adverse effects can be increased when Acemetacin is combined with Rimexolone.Approved
RiociguatThe therapeutic efficacy of Riociguat can be decreased when used in combination with Acemetacin.Approved
RisedronateThe risk or severity of adverse effects can be increased when Acemetacin is combined with Risedronate.Approved, Investigational
RivaroxabanThe risk or severity of bleeding can be increased when Rivaroxaban is combined with Acemetacin.Approved
RofecoxibThe risk or severity of adverse effects can be increased when Rofecoxib is combined with Acemetacin.Approved, Investigational, Withdrawn
RolofyllineThe therapeutic efficacy of Rolofylline can be decreased when used in combination with Acemetacin.Investigational
RosoxacinAcemetacin may increase the neuroexcitatory activities of Rosoxacin.Approved, Investigational
RufloxacinAcemetacin may increase the neuroexcitatory activities of Rufloxacin.Experimental
SabarubicinAcemetacin may decrease the excretion rate of Sabarubicin which could result in a higher serum level.Investigational
SacubitrilThe risk or severity of adverse effects can be increased when Sacubitril is combined with Acemetacin.Approved
SalbutamolThe therapeutic efficacy of Acemetacin can be decreased when used in combination with Salbutamol.Approved, Vet Approved
SalicylamideThe risk or severity of adverse effects can be increased when Salicylamide is combined with Acemetacin.Approved
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Acemetacin.Approved, Investigational, Vet Approved
SalmeterolThe therapeutic efficacy of Acemetacin can be decreased when used in combination with Salmeterol.Approved
SalsalateThe risk or severity of adverse effects can be increased when Salsalate is combined with Acemetacin.Approved
SaprisartanThe therapeutic efficacy of Saprisartan can be decreased when used in combination with Acemetacin.Experimental
SaralasinThe risk or severity of adverse effects can be increased when Saralasin is combined with Acemetacin.Investigational
SarilumabSarilumab may increase the immunosuppressive activities of Acemetacin.Approved, Investigational
SelexipagThe therapeutic efficacy of Selexipag can be decreased when used in combination with Acemetacin.Approved
SemapimodThe risk or severity of adverse effects can be increased when Semapimod is combined with Acemetacin.Investigational
SeratrodastThe risk or severity of adverse effects can be increased when Seratrodast is combined with Acemetacin.Approved
SerrapeptaseThe risk or severity of adverse effects can be increased when Serrapeptase is combined with Acemetacin.Investigational
SisomicinAcemetacin may decrease the excretion rate of Sisomicin which could result in a higher serum level.Investigational
SitafloxacinAcemetacin may increase the neuroexcitatory activities of Sitafloxacin.Experimental, Investigational
SitaxentanThe therapeutic efficacy of Sitaxentan can be decreased when used in combination with Acemetacin.Approved, Investigational, Withdrawn
Sodium phosphateSodium phosphate may increase the nephrotoxic activities of Acemetacin.Approved
SotalolThe therapeutic efficacy of Acemetacin can be decreased when used in combination with Sotalol.Approved
SP1049CAcemetacin may decrease the excretion rate of SP1049C which could result in a higher serum level.Investigational
SparfloxacinAcemetacin may increase the neuroexcitatory activities of Sparfloxacin.Approved, Investigational
SpectinomycinAcemetacin may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Approved, Investigational, Vet Approved
SpiradolineThe therapeutic efficacy of Spiradoline can be decreased when used in combination with Acemetacin.Investigational
SpiraprilThe therapeutic efficacy of Spirapril can be decreased when used in combination with Acemetacin.Approved
SpironolactoneThe therapeutic efficacy of Spironolactone can be decreased when used in combination with Acemetacin.Approved
SRT501The risk or severity of adverse effects can be increased when SRT501 is combined with Acemetacin.Investigational
StreptomycinAcemetacin may decrease the excretion rate of Streptomycin which could result in a higher serum level.Approved, Vet Approved
StreptozocinAcemetacin may decrease the excretion rate of Streptozocin which could result in a higher serum level.Approved, Investigational
SuccinylcholineThe therapeutic efficacy of Acemetacin can be decreased when used in combination with Succinylcholine.Approved
SulfasalazineThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Acemetacin.Approved
SulfinpyrazoneSulfinpyrazone may decrease the excretion rate of Acemetacin which could result in a higher serum level.Approved
SulindacThe risk or severity of adverse effects can be increased when Sulindac is combined with Acemetacin.Approved, Investigational
SulodexideThe risk or severity of bleeding can be increased when Sulodexide is combined with Acemetacin.Approved, Investigational
SulprostoneThe therapeutic efficacy of Sulprostone can be decreased when used in combination with Acemetacin.Investigational
SuprofenThe risk or severity of adverse effects can be increased when Suprofen is combined with Acemetacin.Approved, Withdrawn
SuxibuzoneThe risk or severity of adverse effects can be increased when Suxibuzone is combined with Acemetacin.Experimental
SynephrineThe therapeutic efficacy of Acemetacin can be decreased when used in combination with Synephrine.Experimental
TacrolimusAcemetacin may increase the nephrotoxic activities of Tacrolimus.Approved, Investigational
TafluprostThe therapeutic efficacy of Tafluprost can be decreased when used in combination with Acemetacin.Approved
TalinololThe therapeutic efficacy of Talinolol can be decreased when used in combination with Acemetacin.Investigational
TalniflumateThe risk or severity of adverse effects can be increased when Talniflumate is combined with Acemetacin.Approved
TarenflurbilThe risk or severity of adverse effects can be increased when Tarenflurbil is combined with Acemetacin.Investigational
TasosartanThe risk or severity of adverse effects can be increased when Tasosartan is combined with Acemetacin.Approved
Technetium Tc-99m etidronateThe risk or severity of adverse effects can be increased when Acemetacin is combined with Technetium Tc-99m etidronate.Approved
Technetium Tc-99m medronateThe risk or severity of adverse effects can be increased when Acemetacin is combined with Technetium Tc-99m medronate.Approved
TelmisartanThe therapeutic efficacy of Telmisartan can be decreased when used in combination with Acemetacin.Approved, Investigational
TemafloxacinAcemetacin may increase the neuroexcitatory activities of Temafloxacin.Withdrawn
TemocaprilThe therapeutic efficacy of Temocapril can be decreased when used in combination with Acemetacin.Experimental, Investigational
TenidapThe risk or severity of adverse effects can be increased when Tenidap is combined with Acemetacin.Experimental
Tenofovir disoproxilThe risk or severity of adverse effects can be increased when Acemetacin is combined with Tenofovir disoproxil.Approved, Investigational
TenoxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Acemetacin.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Tepoxalin is combined with Acemetacin.Vet Approved
TerbutalineThe therapeutic efficacy of Acemetacin can be decreased when used in combination with Terbutaline.Approved
TeriflunomideThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Acemetacin.Approved
TerlipressinThe therapeutic efficacy of Terlipressin can be decreased when used in combination with Acemetacin.Approved, Investigational
TertatololAcemetacin may decrease the antihypertensive activities of Tertatolol.Experimental
TetrahydropalmatineThe therapeutic efficacy of Tetrahydropalmatine can be decreased when used in combination with Acemetacin.Investigational
TheobromineThe therapeutic efficacy of Theobromine can be decreased when used in combination with Acemetacin.Approved, Investigational
TheodrenalineThe therapeutic efficacy of Theodrenaline can be decreased when used in combination with Acemetacin.Investigational
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Acemetacin.Approved
TiboloneThe therapeutic efficacy of Tibolone can be decreased when used in combination with Acemetacin.Approved, Investigational
TicrynafenThe therapeutic efficacy of Ticrynafen can be decreased when used in combination with Acemetacin.Withdrawn
Tiludronic acidThe risk or severity of adverse effects can be increased when Acemetacin is combined with Tiludronic acid.Approved, Investigational, Vet Approved
TimololThe therapeutic efficacy of Timolol can be decreased when used in combination with Acemetacin.Approved
TinoridineThe risk or severity of adverse effects can be increased when Tinoridine is combined with Acemetacin.Investigational
TixocortolThe risk or severity of adverse effects can be increased when Acemetacin is combined with Tixocortol.Approved, Withdrawn
TobramycinAcemetacin may decrease the excretion rate of Tobramycin which could result in a higher serum level.Approved, Investigational
TolazolineThe therapeutic efficacy of Tolazoline can be decreased when used in combination with Acemetacin.Approved, Vet Approved
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Acemetacin.Approved, Investigational
TolmetinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Acemetacin.Approved
TolonidineThe therapeutic efficacy of Tolonidine can be decreased when used in combination with Acemetacin.Experimental
TolvaptanThe therapeutic efficacy of Tolvaptan can be decreased when used in combination with Acemetacin.Approved
TorasemideThe therapeutic efficacy of Torasemide can be decreased when used in combination with Acemetacin.Approved
TrandolaprilThe therapeutic efficacy of Trandolapril can be decreased when used in combination with Acemetacin.Approved
TranilastThe risk or severity of adverse effects can be increased when Tranilast is combined with Acemetacin.Approved, Investigational
TravoprostThe therapeutic efficacy of Travoprost can be decreased when used in combination with Acemetacin.Approved
TreprostinilThe therapeutic efficacy of Treprostinil can be decreased when used in combination with Acemetacin.Approved, Investigational
TriamcinoloneThe risk or severity of adverse effects can be increased when Acemetacin is combined with Triamcinolone.Approved, Vet Approved
TriamtereneThe risk or severity of renal failure can be increased when Triamterene is combined with Acemetacin.Approved
TribenosideThe risk or severity of adverse effects can be increased when Tribenoside is combined with Acemetacin.Experimental
TrichlormethiazideThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Acemetacin.Approved, Vet Approved
TrifluoroethanolThe therapeutic efficacy of Acemetacin can be decreased when used in combination with Trifluoroethanol.Experimental
TrimazosinThe therapeutic efficacy of Trimazosin can be decreased when used in combination with Acemetacin.Experimental
TrimethaphanThe therapeutic efficacy of Trimethaphan can be decreased when used in combination with Acemetacin.Approved, Investigational
TriptolideThe risk or severity of adverse effects can be increased when Triptolide is combined with Acemetacin.Investigational
TrolamineThe therapeutic efficacy of Acemetacin can be decreased when used in combination with Trolamine.Approved, Experimental
TrolnitrateThe therapeutic efficacy of Acemetacin can be decreased when used in combination with Trolnitrate.Experimental
TrovafloxacinAcemetacin may increase the neuroexcitatory activities of Trovafloxacin.Approved, Investigational, Withdrawn
TroxerutinThe risk or severity of bleeding can be increased when Troxerutin is combined with Acemetacin.Investigational
TulobuterolThe therapeutic efficacy of Acemetacin can be decreased when used in combination with Tulobuterol.Investigational
UlaritideThe therapeutic efficacy of Ularitide can be decreased when used in combination with Acemetacin.Investigational
UlobetasolThe risk or severity of adverse effects can be increased when Acemetacin is combined with Ulobetasol.Approved
UnoprostoneThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Acemetacin.Approved, Investigational
UrapidilThe therapeutic efficacy of Urapidil can be decreased when used in combination with Acemetacin.Investigational
ValdecoxibThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Acemetacin.Approved, Investigational, Withdrawn
ValrubicinAcemetacin may decrease the excretion rate of Valrubicin which could result in a higher serum level.Approved
ValsartanThe therapeutic efficacy of Valsartan can be decreased when used in combination with Acemetacin.Approved, Investigational
VancomycinThe serum concentration of Vancomycin can be increased when it is combined with Acemetacin.Approved
ViminolThe therapeutic efficacy of Acemetacin can be decreased when used in combination with Viminol.Experimental
VincamineThe therapeutic efficacy of Vincamine can be decreased when used in combination with Acemetacin.Experimental
VinpocetineThe therapeutic efficacy of Vinpocetine can be decreased when used in combination with Acemetacin.Investigational
WarfarinThe risk or severity of bleeding can be increased when Warfarin is combined with Acemetacin.Approved
XimelagatranThe risk or severity of bleeding can be increased when Ximelagatran is combined with Acemetacin.Approved, Investigational, Withdrawn
XipamideThe therapeutic efficacy of Xipamide can be decreased when used in combination with Acemetacin.Experimental
XylometazolineThe therapeutic efficacy of Xylometazoline can be decreased when used in combination with Acemetacin.Approved, Investigational
ZaltoprofenThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Acemetacin.Approved, Investigational
ZileutonThe risk or severity of adverse effects can be increased when Zileuton is combined with Acemetacin.Approved, Investigational, Withdrawn
ZofenoprilThe therapeutic efficacy of Zofenopril can be decreased when used in combination with Acemetacin.Experimental
Zoledronic acidThe risk or severity of adverse effects can be increased when Acemetacin is combined with Zoledronic acid.Approved
ZomepiracThe risk or severity of adverse effects can be increased when Zomepirac is combined with Acemetacin.Withdrawn
Zoptarelin doxorubicinAcemetacin may decrease the excretion rate of Zoptarelin doxorubicin which could result in a higher serum level.Investigational
ZorubicinAcemetacin may decrease the excretion rate of Zorubicin which could result in a higher serum level.Experimental
Food Interactions
Not Available

References

General References
  1. Wada Y, Nakamura M, Kogo H, Aizawa Y: Inhibitory effect of acemetacin, a prodrug of indomethacin, on prostaglandin E2 release from inflamed synovial tissue. Jpn J Pharmacol. 1984 Apr;34(4):468-70. [PubMed:6587139]
  2. Jacobi H, Dell HD: [On the pharmacodynamics of acemetacin (author's transl)]. Arzneimittelforschung. 1980;30(8A):1348-62. [PubMed:6968219]
  3. Jones RW, Collins AJ, Notarianni LJ, Sedman E: The comparative pharmacokinetics of acemetacin in young subjects and elderly patients. Br J Clin Pharmacol. 1991 May;31(5):543-5. [PubMed:1888622]
  4. Dell HD, Doersing M, Fischer W, Jacobi H, Kamp R, Kohler G, Schollnhammer G: [Metabolism and pharmacokinetics of acemetacin in man (author's transl)]. Arzneimittelforschung. 1980;30(8A):1391-8. [PubMed:7191306]
  5. Ochs HR, Schuppan U, Greenblatt DJ, Abernethy DR: Reduced distribution and clearance of acetaminophen in patients with congestive heart failure. J Cardiovasc Pharmacol. 1983 Jul-Aug;5(4):697-9. [PubMed:6193370]
  6. Acton A. (2011). Issues in Pharmacology, Pharmacy, Drug Research and Drug Innovation . ScholarlyEditions.
  7. Sneader W. (2005). Drug discovery a history. Wiley.
  8. Chian R., Nargund G. and Huang J. (2017). Development of In vitro maturation for human oocytes. Springer.
  9. Seyffart G. (1992). Drug dosage in renal insufficiency (2nd ed.). Springer Science+Business Media Dordrecht.
  10. Rantudil label [Link]
  11. Emflex label [Link]
  12. Vademecum [Link]
External Links
KEGG Drug
D01582
PubChem Compound
1981
PubChem Substance
347829316
ChemSpider
1904
BindingDB
50336272
ChEBI
31162
ChEMBL
CHEMBL189171
PharmGKB
PA166049184
Wikipedia
Acemetacin
ATC Codes
M01AB11 — Acemetacin
MSDS
Download (32.4 KB)

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)151.5ºC'MSDS'
boiling point (°C)637ºC'MSDS'
water solubilitySlightly soluble'MSDS'
logP4.49Lead Optimization for Medicinal Chemists. Zaragoza Dorwald F. (2012). Wiley-VCH
pKa2.6'MSDS'
Predicted Properties
PropertyValueSource
Water Solubility0.00229 mg/mLALOGPS
logP3.71ALOGPS
logP3.15ChemAxon
logS-5.3ALOGPS
pKa (Strongest Acidic)3.26ChemAxon
pKa (Strongest Basic)-2.3ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area94.83 Å2ChemAxon
Rotatable Bond Count7ChemAxon
Refractivity105.66 m3·mol-1ChemAxon
Polarizability41.23 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-004i-9000000000-a88b981f972b7490041c
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-004i-9000000000-5022ac71b0218e05c255
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-004i-9010000000-7313a9e1ea4e6eadd36a
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-004i-9010000000-06c9e0b7be55ee33883e
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-004i-9010000000-c018c587e277a577b1dc
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-004i-9110000000-579c64350d45101c2939
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-014i-0210900000-e952722b47bc6f5bce93
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-000i-0900000000-c5202d3fb48f6df18dce
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-000i-0900000000-b5f7e4a388e86e743206
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-000i-0900000000-47ab4028894c896b53b3
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-000i-0900000000-50c13e48179e8e0a0fb2
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-000i-0911000000-28e04265af736ccc17a9
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-000i-0900000000-85d2686103fd853155ba
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-000i-0900000000-5add7b0f737e82efdd15
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-000i-0900000000-095e5b098c5f7dd6bc5a
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-000i-0900000000-8939159ece125ac8a14b
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-002r-1900000000-f0f214f31c71a92a8b3d
MS/MS Spectrum - , positiveLC-MS/MSsplash10-000i-0901200000-1a6af5ef67d07b4da751
MS/MS Spectrum - , positiveLC-MS/MSsplash10-000i-3900000000-cf46a091c4414a82a401

Taxonomy

Description
This compound belongs to the class of organic compounds known as benzoylindoles. These are organic compounds containing an indole attached to a benzoyl moiety through the acyl group.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Indoles and derivatives
Sub Class
Benzoylindoles
Direct Parent
Benzoylindoles
Alternative Parents
Indole-3-acetic acid derivatives / Indolecarboxylic acids and derivatives / 3-alkylindoles / 4-halobenzoic acids and derivatives / Anisoles / Benzoyl derivatives / Alkyl aryl ethers / Chlorobenzenes / Dicarboxylic acids and derivatives / Aryl chlorides
show 11 more
Substituents
Benzoylindole / Indole-3-acetic acid derivative / Indolecarboxylic acid derivative / 4-halobenzoic acid or derivatives / Halobenzoic acid or derivatives / 3-alkylindole / Benzoic acid or derivatives / Indole / Anisole / Benzoyl
show 27 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
monocarboxylic acid, carboxylic ester, monochlorobenzenes, N-acylindole, indol-3-yl carboxylic acid (CHEBI:31162)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Prostaglandin-endoperoxide synthase activity
Specific Function
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Involved in the constitutive production of prostanoids in particular in the stomach and platelets. In gas...
Gene Name
PTGS1
Uniprot ID
P23219
Uniprot Name
Prostaglandin G/H synthase 1
Molecular Weight
68685.82 Da
References
  1. Sneader W. (2005). Drug discovery a history. Wiley.
  2. Chian R., Nargund G. and Huang J. (2017). Development of In vitro maturation for human oocytes. Springer.
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Prostaglandin-endoperoxide synthase activity
Specific Function
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Constitutively expressed in some tissues in physiological conditions, such as the endothelium, kidney and...
Gene Name
PTGS2
Uniprot ID
P35354
Uniprot Name
Prostaglandin G/H synthase 2
Molecular Weight
68995.625 Da
References
  1. Sneader W. (2005). Drug discovery a history. Wiley.
  2. Chian R., Nargund G. and Huang J. (2017). Development of In vitro maturation for human oocytes. Springer.

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Substrate
General Function
Glucuronosyltransferase activity
Specific Function
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds.Its unique specificity for 3,4-catechol estrogens and estriol su...
Gene Name
UGT2B7
Uniprot ID
P16662
Uniprot Name
UDP-glucuronosyltransferase 2B7
Molecular Weight
60694.12 Da
References
  1. Seyffart G. (1992). Drug dosage in renal insufficiency (2nd ed.). Springer Science+Business Media Dordrecht.

Transporters

Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Substrate
General Function
Transporter activity
Specific Function
Mediates export of organic anions and drugs from the cytoplasm. Mediates ATP-dependent transport of glutathione and glutathione conjugates, leukotriene C4, estradiol-17-beta-o-glucuronide, methotre...
Gene Name
ABCC1
Uniprot ID
P33527
Uniprot Name
Multidrug resistance-associated protein 1
Molecular Weight
171589.5 Da
References
  1. Dittmar T. and Zanker K. (2009). Stem cell biology in health and disease. Springer.

Drug created on June 23, 2017 14:48 / Updated on March 02, 2018 04:31